Mohammed Tarek Hasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed Tarek Hasan has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed A. Aldemerdash
Faculty of Medicine, Sohag University, Sohag, Egypt
3 shared publications - Mohammed Abdellatif
Negida Research Academy, Arlington, Virginia, USA
3 shared publications - Naema Hamouda
Negida Research Academy, Arlington, Virginia, USA
3 shared publications - Ahmed Aldemerdash
Faculty of Medicine, Sohag University, Sohag, Egypt
2 shared publications - Ali Saad Al-Shammari
Department of Internal Medicine, College of Medicine University of Baghdad Baghdad Iraq
2 shared publications - Amira A. Aboali
Department of Diagnostic and Interventional Radiology, Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes, Damanhour, Egypt
2 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e98718
Open-Source R Shiny Dashboard (Global Burden of Disease Analysis Suite) for Multimethod Burden of Disease Research: Development and Evaluation Study
Background: The Global Burden of Disease (GBD) study provides the most comprehensive global burden estimates available, but translating GBD data downloads into structured analyses requires an integrated, multimethod workflow spanning trend estimation, changepoint detection, demographic decomposition, frontier benchmarking, and health inequality measurement. Existing tools cover portions of this workflow, but none integrate it end-to-end in a code-free interface, creating a substantial technical barrier, particularly for investigators in resource-limited settings. Objective: This study aimed to develop and release the GBD Analysis Suite, an open-source R Shiny dashboard that consolidates 11 commonly used analytical modules for GBD-style burden-of-disease research into a single, code-free, web interface supporting user-uploaded data, and to describe its underlying architecture, analytical methodology, and intended applications. Methods: The application was built using R 4.5.3 and the Shiny framework, integrating established statistical packages, including forecast, segmented, openxlsx, ggplot2, plotly, and others, into modules covering data import, choropleth mapping, estimated annual percentage change, joinpoint regression, Kitagawa and Das Gupta decomposition, multimodel time-series forecasting, descriptive visualization, sociodemographic index–based frontier analysis, descriptive age-period-cohort visualization, slope and relative indices of inequality, and batch export. The application accepts Global Health Data Exchange (GHDx)–formatted CSV or Excel files, automatically detects standard variable names, and enforces internal consistency through built-in validation checks. Kitagawa decomposition uses the symmetric mid-point formulation to ensure exact additivity. The three ensemble forecast models (autoregressive integrated moving average [ARIMA], exponential smoothing state-space [ETS], and a feed-forward neural network [NNETAR]) apply Box-Cox log transformation, with an explicit nonnegativity floor applied to the point forecast and prediction intervals of every model. Results: The application is publicly deployed and can be accessed through any modern web browser without requiring local installation. On the bundled 196-country, 34-year demonstration dataset, exporting the full set of outputs completes in approximately 12 seconds at a peak memory footprint of approximately 600 MB. A feature comparison against 5 existing tools (GBD Compare, GBD Foresight, NCI Joinpoint, BAPC, and NordPred) across 14 capability dimensions confirms that the GBD Analysis Suite is the only reviewed platform combining user-uploaded data input with code-free access to all 6 core analytical methods of modern GBD papers. Source code is publicly available under the MIT license. Conclusions: The GBD Analysis Suite lowers the technical barrier to reproducible, multimethod burden of disease analyses. It is designed particularly for researchers in low- and middle-income countries where biostatistical support, commercial software licenses, and high-performance computing are often unavailable. The modular architecture supports flexibility across disease areas, geographies, and time windows, subject to input data compatibility. Community contributions, feature requests, and collaborative extensions are welcomed through the project’s public GitHub repository.
- 11 September 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e98718
Open AccessOpen-Source R Shiny Dashboard (Global Burden of Disease Analysis Suite) for Multimethod Burden of Disease Research: Development and Evaluation Study
Background: The Global Burden of Disease (GBD) study provides the most comprehensive global burden estimates available, but translating GBD data downloads into structured analyses requires an integrated, multimethod workflow spanning trend estimation, changepoint detection, demographic decomposition, frontier benchmarking, and health inequality measurement. Existing tools cover portions of this workflow, but none integrate it end-to-end in a code-free interface, creating a substantial technical barrier, particularly for investigators in resource-limited settings. Objective: This study aimed to develop and release the GBD Analysis Suite, an open-source R Shiny dashboard that consolidates 11 commonly used analytical modules for GBD-style burden-of-disease research into a single, code-free, web interface supporting user-uploaded data, and to describe its underlying architecture, analytical methodology, and intended applications. Methods: The application was built using R 4.5.3 and the Shiny framework, integrating established statistical packages, including forecast, segmented, openxlsx, ggplot2, plotly, and others, into modules covering data import, choropleth mapping, estimated annual percentage change, joinpoint regression, Kitagawa and Das Gupta decomposition, multimodel time-series forecasting, descriptive visualization, sociodemographic index–based frontier analysis, descriptive age-period-cohort visualization, slope and relative indices of inequality, and batch export. The application accepts Global Health Data Exchange (GHDx)–formatted CSV or Excel files, automatically detects standard variable names, and enforces internal consistency through built-in validation checks. Kitagawa decomposition uses the symmetric mid-point formulation to ensure exact additivity. The three ensemble forecast models (autoregressive integrated moving average [ARIMA], exponential smoothing state-space [ETS], and a feed-forward neural network [NNETAR]) apply Box-Cox log transformation, with an explicit nonnegativity floor applied to the point forecast and prediction intervals of every model. Results: The application is publicly deployed and can be accessed through any modern web browser without requiring local installation. On the bundled 196-country, 34-year demonstration dataset, exporting the full set of outputs completes in approximately 12 seconds at a peak memory footprint of approximately 600 MB. A feature comparison against 5 existing tools (GBD Compare, GBD Foresight, NCI Joinpoint, BAPC, and NordPred) across 14 capability dimensions confirms that the GBD Analysis Suite is the only reviewed platform combining user-uploaded data input with code-free access to all 6 core analytical methods of modern GBD papers. Source code is publicly available under the MIT license. Conclusions: The GBD Analysis Suite lowers the technical barrier to reproducible, multimethod burden of disease analyses. It is designed particularly for researchers in low- and middle-income countries where biostatistical support, commercial software licenses, and high-performance computing are often unavailable. The modular architecture supports flexibility across disease areas, geographies, and time windows, subject to input data compatibility. Community contributions, feature requests, and collaborative extensions are welcomed through the project’s public GitHub repository.
- Open Access
- 17 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
GBD Analysis Suite: An Open-Source R Shiny Dashboard for Multi-Method Burden of Disease Research (Preprint)
BACKGROUND The Global Burden of Disease (GBD) study provides the most comprehensive cross-national burden estimates available, but translating GBD data downloads into publication-ready analyses requires an integrated, multi-method workflow spanning trend estimation, changepoint detection, demographic decomposition, forecasting, frontier benchmarking, and health inequality measurement. Existing tools cover portions of this workflow but none integrates it end to end in a code-free interface, creating a disproportionate barrier for investigators in resource-limited settings. OBJECTIVE To develop and release an open-source R Shiny dashboard, the GBD Analysis Suite, that integrates the 11 analytical modules required for a standard GBD burden of disease study into a single user-uploadable, code-free web interface, and to describe its architecture, methodology, and intended use. METHODS The application was built using R 4.5.3 and the Shiny framework, integrating established statistical packages (forecast, segmented, openxlsx, ggplot2, plotly, and others) into 11 modules covering data import, choropleth mapping, estimated annual percentage change (EAPC), joinpoint regression, Kitagawa and Das Gupta decomposition, multi-model time-series forecasting, descriptive visualization, Socio-demographic Index (SDI) based frontier analysis, age period cohort (APC) visualization, slope and relative index of inequality (SII and RII), and batch export. The application accepts any GHDx-formatted CSV or Excel file, auto-detects standard column names, and enforces internal consistency by construction. Kitagawa decomposition uses the symmetric mid-point formulation to guarantee exact additivity, and all forecast models use Box-Cox log transformation with bias-corrected back-transformation to guarantee non-negative point estimates and prediction intervals. RESULTS The application is deployed at https://bela2003.shinyapps.io/GBD-Analysis-Suite/ and runs in any modern web browser without local installation. On the bundled 204-country, 34-year demonstration dataset, a complete batch export (an 8-sheet Excel workbook plus 10 or more figures) completes in approximately 90 seconds at a peak memory footprint of approximately 800 MB. A feature comparison against five existing tools (GBD Compare, GBD Foresight, NCI Joinpoint, BAPC, NordPred) across 14 capability dimensions shows that the GBD Analysis Suite is the only reviewed platform combining user-uploaded data input with code-free access to all six core analytical methods of modern GBD papers. Source code is publicly available at https://github.com/levai-2003/GBD-Analysis-Suite under the MIT license. CONCLUSIONS The GBD Analysis Suite lowers the technical barrier to reproducible, multi-method burden of disease analyses. It is designed particularly for researchers in low- and middle-income countries where biostatistical support, commercial software licenses, and high-performance computing are often unavailable. The modular design imposes no structural limitations on disease area, geography, or time window.
- 17 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessGBD Analysis Suite: An Open-Source R Shiny Dashboard for Multi-Method Burden of Disease Research (Preprint)
BACKGROUND The Global Burden of Disease (GBD) study provides the most comprehensive cross-national burden estimates available, but translating GBD data downloads into publication-ready analyses requires an integrated, multi-method workflow spanning trend estimation, changepoint detection, demographic decomposition, forecasting, frontier benchmarking, and health inequality measurement. Existing tools cover portions of this workflow but none integrates it end to end in a code-free interface, creating a disproportionate barrier for investigators in resource-limited settings. OBJECTIVE To develop and release an open-source R Shiny dashboard, the GBD Analysis Suite, that integrates the 11 analytical modules required for a standard GBD burden of disease study into a single user-uploadable, code-free web interface, and to describe its architecture, methodology, and intended use. METHODS The application was built using R 4.5.3 and the Shiny framework, integrating established statistical packages (forecast, segmented, openxlsx, ggplot2, plotly, and others) into 11 modules covering data import, choropleth mapping, estimated annual percentage change (EAPC), joinpoint regression, Kitagawa and Das Gupta decomposition, multi-model time-series forecasting, descriptive visualization, Socio-demographic Index (SDI) based frontier analysis, age period cohort (APC) visualization, slope and relative index of inequality (SII and RII), and batch export. The application accepts any GHDx-formatted CSV or Excel file, auto-detects standard column names, and enforces internal consistency by construction. Kitagawa decomposition uses the symmetric mid-point formulation to guarantee exact additivity, and all forecast models use Box-Cox log transformation with bias-corrected back-transformation to guarantee non-negative point estimates and prediction intervals. RESULTS The application is deployed at https://bela2003.shinyapps.io/GBD-Analysis-Suite/ and runs in any modern web browser without local installation. On the bundled 204-country, 34-year demonstration dataset, a complete batch export (an 8-sheet Excel workbook plus 10 or more figures) completes in approximately 90 seconds at a peak memory footprint of approximately 800 MB. A feature comparison against five existing tools (GBD Compare, GBD Foresight, NCI Joinpoint, BAPC, NordPred) across 14 capability dimensions shows that the GBD Analysis Suite is the only reviewed platform combining user-uploaded data input with code-free access to all six core analytical methods of modern GBD papers. Source code is publicly available at https://github.com/levai-2003/GBD-Analysis-Suite under the MIT license. CONCLUSIONS The GBD Analysis Suite lowers the technical barrier to reproducible, multi-method burden of disease analyses. It is designed particularly for researchers in low- and middle-income countries where biostatistical support, commercial software licenses, and high-performance computing are often unavailable. The modular design imposes no structural limitations on disease area, geography, or time window.
- Open Access
- 17 April 2026
- Published by Springer Nature in Current Emergency and Hospital Medicine Reports
- Vol. 14 (1) , 8
Risk Factors for Recurrent DKA in Children and Adolescents with Established Diabetes: A Systematic Review and Meta-Analysis
Purpose of Review: Despite advances in diabetes management, recurrent diabetic ketoacidosis (DKA) remains a common and largely preventable complication in paediatric patients with type 1 diabetes mellitus (T1DM). This systematic review and meta-analysis aimed to synthesise available evidence on risk factors associated with recurrent DKA in children and adolescents. Recent Findings: We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library from inception to October 2025. Observational studies involving children and adolescents (< 21 years) with established type 1 diabetes mellitus and biochemically confirmed DKA were included. Random-effects meta-analyses were performed for predefined predictors, reporting pooled odds ratios (ORs) with 95% confidence intervals (CI). Twelve observational studies comprising 58,911 paediatric patients were included. A prior episode of DKA was the strongest predictor of recurrence, conferring an almost eightfold increased risk (OR = 7.97, 95% CI 4.33–14.67). Longer diabetes duration of 12–15 years was also associated with increased recurrence risk (OR = 1.94, 95% CI 1.21–3.11), whereas duration of 5–11 years was not (OR = 1.13, 95% CI 0.76–1.69). Female sex was not significantly associated with recurrence in the primary analysis. Overall risk of bias was moderate across studies. Summary: Prior DKA episodes and longer disease duration are key predictors of recurrent DKA in paediatric T1DM. Targeted prevention strategies following an initial DKA episode are urgently needed, supported by future prospective research.
- 17 April 2026
- Published by Springer Nature in Current Emergency and Hospital Medicine Reports
- Vol. 14 (1) , 8
Open AccessRisk Factors for Recurrent DKA in Children and Adolescents with Established Diabetes: A Systematic Review and Meta-Analysis
Purpose of Review: Despite advances in diabetes management, recurrent diabetic ketoacidosis (DKA) remains a common and largely preventable complication in paediatric patients with type 1 diabetes mellitus (T1DM). This systematic review and meta-analysis aimed to synthesise available evidence on risk factors associated with recurrent DKA in children and adolescents. Recent Findings: We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library from inception to October 2025. Observational studies involving children and adolescents (< 21 years) with established type 1 diabetes mellitus and biochemically confirmed DKA were included. Random-effects meta-analyses were performed for predefined predictors, reporting pooled odds ratios (ORs) with 95% confidence intervals (CI). Twelve observational studies comprising 58,911 paediatric patients were included. A prior episode of DKA was the strongest predictor of recurrence, conferring an almost eightfold increased risk (OR = 7.97, 95% CI 4.33–14.67). Longer diabetes duration of 12–15 years was also associated with increased recurrence risk (OR = 1.94, 95% CI 1.21–3.11), whereas duration of 5–11 years was not (OR = 1.13, 95% CI 0.76–1.69). Female sex was not significantly associated with recurrence in the primary analysis. Overall risk of bias was moderate across studies. Summary: Prior DKA episodes and longer disease duration are key predictors of recurrent DKA in paediatric T1DM. Targeted prevention strategies following an initial DKA episode are urgently needed, supported by future prospective research.
- Open Access
- 13 February 2026
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 30 (2) , 155-164
Diagnostic Accuracy of Point-of-care Ultrasonography for Confirming Endotracheal Tube Placement in Adults: An Updated Systematic Review and Meta-analysis
Point-of-care ultrasonography (POCUS) is increasingly used to confirm endotracheal tube (ETT) placement; however, its overall diagnostic accuracy and speed compared with standard methods in adult emergency and critical care settings remain uncertain. We conducted a systematic review and meta-analysis of observational studies through May 2025 that evaluated POCUS for confirming ETT placement in adults (≥18 years) in emergency departments (EDs) and intensive care units (ICUs). Thirty studies met the inclusion criteria. Point-of-care ultrasonography achieved a pooled sensitivity of 0.91 and a specificity of 0.98. The area under the curve (AUC) was 0.96 [95% confidence interval (CI): 0.88–1.00]. The mean time-to-confirmation was 19.62 seconds for POCUS vs 22.46 seconds for standard methods; however, this finding should be interpreted with caution due to extreme heterogeneity (I² > 99%). Point-of-care ultrasonography is a highly accurate, rapid, and reliable method for confirming ETT placement in adult ED and ICU settings. It demonstrates diagnostic performance comparable to previously reported capnography performance and provides unique advantages as an adjunctive tool, especially in scenarios where capnography may be unreliable. Alsabri M, Elsnhory AB, Hasan MT, McClean CH, Abouelmagd K, Abady E, et al. Diagnostic Accuracy of Point-of-care Ultrasonography for Confirming Endotracheal Tube Placement in Adults: An Updated Systematic Review and Meta-analysis. Indian J Crit Care Med 2026;30(2):155–164.
- 13 February 2026
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 30 (2) , 155-164
Open AccessDiagnostic Accuracy of Point-of-care Ultrasonography for Confirming Endotracheal Tube Placement in Adults: An Updated Systematic Review and Meta-analysis
Point-of-care ultrasonography (POCUS) is increasingly used to confirm endotracheal tube (ETT) placement; however, its overall diagnostic accuracy and speed compared with standard methods in adult emergency and critical care settings remain uncertain. We conducted a systematic review and meta-analysis of observational studies through May 2025 that evaluated POCUS for confirming ETT placement in adults (≥18 years) in emergency departments (EDs) and intensive care units (ICUs). Thirty studies met the inclusion criteria. Point-of-care ultrasonography achieved a pooled sensitivity of 0.91 and a specificity of 0.98. The area under the curve (AUC) was 0.96 [95% confidence interval (CI): 0.88–1.00]. The mean time-to-confirmation was 19.62 seconds for POCUS vs 22.46 seconds for standard methods; however, this finding should be interpreted with caution due to extreme heterogeneity (I² > 99%). Point-of-care ultrasonography is a highly accurate, rapid, and reliable method for confirming ETT placement in adult ED and ICU settings. It demonstrates diagnostic performance comparable to previously reported capnography performance and provides unique advantages as an adjunctive tool, especially in scenarios where capnography may be unreliable. Alsabri M, Elsnhory AB, Hasan MT, McClean CH, Abouelmagd K, Abady E, et al. Diagnostic Accuracy of Point-of-care Ultrasonography for Confirming Endotracheal Tube Placement in Adults: An Updated Systematic Review and Meta-analysis. Indian J Crit Care Med 2026;30(2):155–164.
- 19 January 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (4) , F352-F359
Effect of different feeding approaches on growth, neonatal morbidities, mortality and neurodevelopmental outcome in preterm infants: a systematic review and network meta-analysis
Objective: To compare feeding strategies on preterm infants’ growth during hospitalisation, neonatal morbidities, mortality and neurodevelopmental outcome (NDO) at 18–26 months corrected age. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension statement for network meta-analysis . We searched five medical databases for randomised controlled trials comparing different feeding approaches in preterm infants and their effects on growth, neonatal morbidities, mortality and NDO. The Cochrane Collaboration’s tool was used to assess the risk of bias. We used a random-effects model. Pooled mean differences (MD) or risk ratios with 95% CIs were calculated. Results: Ninety-five studies (9663 infants) were included. Human milk (HM) with bovine milk fortifier (BMF) (adjusted according to blood urea nitrogen) achieved the best length increment (MD=0.56 cm/week; 95% CI 0.19 to 0.93). Notably, HM+BMF (3.5 gm/kg/d protein) showed the best head circumference growth (MD 0.46 cm/week; 95% CI 0.10 to 0.81) but no significant difference in weight gain. There were no significant differences in neonatal morbidities/mortality. While MOM|+PTF (supp) displayed significantly lower NDO delay in the domain of mild cognitive delay. Conclusion: Overall, there is a lack of strong evidence to support a specific enteral feeding strategy and further high-quality research is required. Targeted HM fortification appears to improve head growth, while adjusted fortification enhances length. Given the significant inconsistency detected, which may compromise the reliability of the network estimates, these results must be interpreted carefully.
- 19 January 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (4) , F352-F359
Effect of different feeding approaches on growth, neonatal morbidities, mortality and neurodevelopmental outcome in preterm infants: a systematic review and network meta-analysis
Objective: To compare feeding strategies on preterm infants’ growth during hospitalisation, neonatal morbidities, mortality and neurodevelopmental outcome (NDO) at 18–26 months corrected age. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension statement for network meta-analysis . We searched five medical databases for randomised controlled trials comparing different feeding approaches in preterm infants and their effects on growth, neonatal morbidities, mortality and NDO. The Cochrane Collaboration’s tool was used to assess the risk of bias. We used a random-effects model. Pooled mean differences (MD) or risk ratios with 95% CIs were calculated. Results: Ninety-five studies (9663 infants) were included. Human milk (HM) with bovine milk fortifier (BMF) (adjusted according to blood urea nitrogen) achieved the best length increment (MD=0.56 cm/week; 95% CI 0.19 to 0.93). Notably, HM+BMF (3.5 gm/kg/d protein) showed the best head circumference growth (MD 0.46 cm/week; 95% CI 0.10 to 0.81) but no significant difference in weight gain. There were no significant differences in neonatal morbidities/mortality. While MOM|+PTF (supp) displayed significantly lower NDO delay in the domain of mild cognitive delay. Conclusion: Overall, there is a lack of strong evidence to support a specific enteral feeding strategy and further high-quality research is required. Targeted HM fortification appears to improve head growth, while adjusted fortification enhances length. Given the significant inconsistency detected, which may compromise the reliability of the network estimates, these results must be interpreted carefully.
- 19 June 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1002, 177797
Efficacy and safety of immune checkpoint inhibitors for advanced or metastatic esophageal squamous cell carcinoma: A network meta-analysis
- 19 June 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1002, 177797
Efficacy and safety of immune checkpoint inhibitors for advanced or metastatic esophageal squamous cell carcinoma: A network meta-analysis
- 2 May 2025
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 42 (16) , 2077-2086
Comparing Umbilical Cord Management Strategies in Nonvigorous Newborns: A Systematic Review and Network Meta-analysis
Nonvigorous newborns often require immediate resuscitation, and early cord clamping (ECC) is the conventional approach. Alternative strategies, such as intact cord resuscitation (ICR) and umbilical cord milking (UCM), may provide additional benefits without compromising safety. To compare the effectiveness and safety of different umbilical cord management strategies for nonvigorous newborns. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines and searched six databases for randomized controlled trials comparing different umbilical cord management approaches in nonvigorous newborns. Outcomes assessed included resuscitation effectiveness, hematological parameters, neonatal morbidities, and mortality. The Cochrane Collaboration tool RoB2 was used to assess the risk of bias. Ten studies with 2,541 newborns were included, with seven studies contributing to the meta-analysis. No significant differences were observed in resuscitation requirements, Apgar scores, or mortality between ECC, ICR, and UCM. However, at 5 minutes, ICR showed a small but statistically significant higher Apgar score compared with other interventions (mean difference [MD] = 0.3, 95% confidence interval [CI] [0.05, 0.55]). Additionally, heart rate was lower in the intact ICM (I-UCM) group (MD = −34.75 beats/min, 95% CI [−61.84, −7.66]). Cut UCM was associated with significantly higher serum ferritin levels at 6 weeks (MD = 40.44 µg/L, 95% CI [26.45, 54.43]). Initial hematocrit levels were also higher in the ICR group compared with ECC. ICR and UCM might be safe and effective alternatives to ECC for nonvigorous newborns, with potential hematological benefits. However, further large-scale studies are needed to confirm these findings and evaluate long-term neurodevelopmental outcomes.
- 2 May 2025
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 42 (16) , 2077-2086
Comparing Umbilical Cord Management Strategies in Nonvigorous Newborns: A Systematic Review and Network Meta-analysis
Nonvigorous newborns often require immediate resuscitation, and early cord clamping (ECC) is the conventional approach. Alternative strategies, such as intact cord resuscitation (ICR) and umbilical cord milking (UCM), may provide additional benefits without compromising safety. To compare the effectiveness and safety of different umbilical cord management strategies for nonvigorous newborns. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines and searched six databases for randomized controlled trials comparing different umbilical cord management approaches in nonvigorous newborns. Outcomes assessed included resuscitation effectiveness, hematological parameters, neonatal morbidities, and mortality. The Cochrane Collaboration tool RoB2 was used to assess the risk of bias. Ten studies with 2,541 newborns were included, with seven studies contributing to the meta-analysis. No significant differences were observed in resuscitation requirements, Apgar scores, or mortality between ECC, ICR, and UCM. However, at 5 minutes, ICR showed a small but statistically significant higher Apgar score compared with other interventions (mean difference [MD] = 0.3, 95% confidence interval [CI] [0.05, 0.55]). Additionally, heart rate was lower in the intact ICM (I-UCM) group (MD = −34.75 beats/min, 95% CI [−61.84, −7.66]). Cut UCM was associated with significantly higher serum ferritin levels at 6 weeks (MD = 40.44 µg/L, 95% CI [26.45, 54.43]). Initial hematocrit levels were also higher in the ICR group compared with ECC. ICR and UCM might be safe and effective alternatives to ECC for nonvigorous newborns, with potential hematological benefits. However, further large-scale studies are needed to confirm these findings and evaluate long-term neurodevelopmental outcomes.
- 1 February 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (6) , 2821-2832
Efficacy of bevacizumab in hereditary hemorrhagic telangiectasia: a systematic review and network meta-analysis
Background Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal multi-systemic vascular dysplasia caused by gene mutations that lead to recurrent epistaxis and other serious complications including mucocutaneous telangiectasias, gastrointestinal bleeding, and arteriovenous malformations. Treatment is limited to symptomatic relief with no approved standard therapy. Bevacizumab is a monoclonal antibody used primarily in treating metastatic malignancies and ophthalmology. Several studies have shown that bevacizumab is effective in the treatment of HHT-related epistaxis with a high safety profile. Purpose This systematic review and network meta-analysis aims to explore the efficacy and safety of bevacizumab in the treatment of HHT epistaxis. Methods A comprehensive literature search was done in many databases, including PubMed, Web of Science, Scopus, and the Cochrane Library. We conducted our network meta-analysis using R version 4.2.2 and R Studio version 2022.07.2. Dichotomous data was analyzed as risk ratio and 95% confidence interval and continuous data as mean difference and 95% confidence interval. Results We included four randomized clinical trials in our network meta-analysis. Different doses of bevacizumab failed to yield any statistically significant difference in reducing the epistaxis severity score, the number of epistaxis episodes, the duration of epistaxis, or improving hemoglobin levels compared to placebo or other comparators. The pooled effect sizes for all outcomes were homogenous. Conclusion Bevacizumab failed to show any significant difference compared to tranexamic acid, estriol, or placebo. These findings underscore the challenges in addressing HHT-related symptoms and highlight the ongoing need for innovative and more effective interventions.
- 1 February 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (6) , 2821-2832
Efficacy of bevacizumab in hereditary hemorrhagic telangiectasia: a systematic review and network meta-analysis
Background Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal multi-systemic vascular dysplasia caused by gene mutations that lead to recurrent epistaxis and other serious complications including mucocutaneous telangiectasias, gastrointestinal bleeding, and arteriovenous malformations. Treatment is limited to symptomatic relief with no approved standard therapy. Bevacizumab is a monoclonal antibody used primarily in treating metastatic malignancies and ophthalmology. Several studies have shown that bevacizumab is effective in the treatment of HHT-related epistaxis with a high safety profile. Purpose This systematic review and network meta-analysis aims to explore the efficacy and safety of bevacizumab in the treatment of HHT epistaxis. Methods A comprehensive literature search was done in many databases, including PubMed, Web of Science, Scopus, and the Cochrane Library. We conducted our network meta-analysis using R version 4.2.2 and R Studio version 2022.07.2. Dichotomous data was analyzed as risk ratio and 95% confidence interval and continuous data as mean difference and 95% confidence interval. Results We included four randomized clinical trials in our network meta-analysis. Different doses of bevacizumab failed to yield any statistically significant difference in reducing the epistaxis severity score, the number of epistaxis episodes, the duration of epistaxis, or improving hemoglobin levels compared to placebo or other comparators. The pooled effect sizes for all outcomes were homogenous. Conclusion Bevacizumab failed to show any significant difference compared to tranexamic acid, estriol, or placebo. These findings underscore the challenges in addressing HHT-related symptoms and highlight the ongoing need for innovative and more effective interventions.
- 10 January 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (2) , 1-11
Evaluation of cord management strategies in intrauterine growth-restricted infants: a systematic review and meta-analysis
Delayed cord clamping (DCC) has been widely adopted in both term and preterm infants to improve neonatal outcomes by increasing blood volume and supporting oxygenation. However, the optimal cord management for intrauterine growth-restricted (IUGR) infants is unclear. To systematically review and meta-analyze the effects of DCC compared to early cord clamping (ECC) in IUGR infants. We followed the PRISMA guidelines for meta-analysis. Six databases were searched for randomized controlled trials (RCTs) and observational studies comparing DCC and ECC in IUGR infants, focusing on neonatal resuscitation measures, hematological parameters, morbidities, and mortality. The Cochrane Collaboration tool and Newcastle–Ottawa scale were used for RCTs and observational studies, respectively. Eight studies with 1531 participants were included, comprising six RCTs and two observational studies. Serum ferritin at 3 months and initial Hb were significantly higher in the DCC group (MD: 36.16 ng/ml [95% CI: 34.09, 38.24]), (MD: 1.64 gm/dl [95%CI: 0.88, 2.4]) respectively. The risk of polycythemia was higher in the DCC group (RR 1.88, 95% CI [1.27, 2.8]), without an increase in the peak total serum bilirubin or the need for exchange transfusion. Conclusion: DCC may be beneficial and safe in IUGR infants, improving hematological parameters without affecting neonatal morbidity and mortality. Further high-quality, large trials are needed to confirm these findings and assess neurodevelopmental impact.
- 10 January 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (2) , 1-11
Evaluation of cord management strategies in intrauterine growth-restricted infants: a systematic review and meta-analysis
Delayed cord clamping (DCC) has been widely adopted in both term and preterm infants to improve neonatal outcomes by increasing blood volume and supporting oxygenation. However, the optimal cord management for intrauterine growth-restricted (IUGR) infants is unclear. To systematically review and meta-analyze the effects of DCC compared to early cord clamping (ECC) in IUGR infants. We followed the PRISMA guidelines for meta-analysis. Six databases were searched for randomized controlled trials (RCTs) and observational studies comparing DCC and ECC in IUGR infants, focusing on neonatal resuscitation measures, hematological parameters, morbidities, and mortality. The Cochrane Collaboration tool and Newcastle–Ottawa scale were used for RCTs and observational studies, respectively. Eight studies with 1531 participants were included, comprising six RCTs and two observational studies. Serum ferritin at 3 months and initial Hb were significantly higher in the DCC group (MD: 36.16 ng/ml [95% CI: 34.09, 38.24]), (MD: 1.64 gm/dl [95%CI: 0.88, 2.4]) respectively. The risk of polycythemia was higher in the DCC group (RR 1.88, 95% CI [1.27, 2.8]), without an increase in the peak total serum bilirubin or the need for exchange transfusion. Conclusion: DCC may be beneficial and safe in IUGR infants, improving hematological parameters without affecting neonatal morbidity and mortality. Further high-quality, large trials are needed to confirm these findings and assess neurodevelopmental impact.